Zurcher Kantonalbank Zurich Cantonalbank Has $660.69 Million Holdings in Eli Lilly and Company $LLY

Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Eli Lilly and Company (NYSE:LLY) by 12.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 614,780 shares of the company’s stock after acquiring an additional 66,441 shares during the period. Eli Lilly and Company comprises 1.4% of Zurcher Kantonalbank Zurich Cantonalbank’s investment portfolio, making the stock its 12th biggest holding. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Eli Lilly and Company were worth $660,692,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Maryland Capital Advisors Inc. acquired a new stake in shares of Eli Lilly and Company in the 4th quarter worth about $25,000. Vermillion & White Wealth Management Group LLC lifted its position in shares of Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after buying an additional 16 shares in the last quarter. 10Elms LLP boosted its stake in shares of Eli Lilly and Company by 33.3% in the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after buying an additional 10 shares during the last quarter. Miller Global Investments LLC bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $33,000. Finally, Hopwood Financial Services Inc. grew its holdings in shares of Eli Lilly and Company by 113.6% in the third quarter. Hopwood Financial Services Inc. now owns 47 shares of the company’s stock valued at $36,000 after acquiring an additional 25 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to acquire Kelonia Therapeutics in a deal worth up to $7B to add an in?vivo CAR?T platform and early-stage oncology assets — viewed by analysts as a meaningful step to diversify beyond GLP?1s and build long?term growth. Eli Lilly’s US$7b Kelonia Deal Reshapes Oncology And Valuation Story
• Positive Sentiment: Analysts are upping conviction: Guggenheim raised its price target and maintained a Buy, BMO reiterated Outperform with a $1,300 target, and UBS/Bernstein commentary has been bullish — supporting investor demand after the deal and ahead of earnings. Guggenheim Adjusts Price Target on Eli Lilly
• Positive Sentiment: Topline ACHIEVE?4 results for Foundayo versus insulin glargine and commentary that post?marketing requirements look manageable have reduced regulatory uncertainty around Lilly’s diabetes franchise. That helps near?term sentiment on earnings and guidance. Why You Should Not Worry About Eli Lilly and Company’s Foundayo Treatment Prospects
• Neutral Sentiment: Debate over valuation persists — some pieces argue LLY’s premium multiple is justified by growth, others note a wide gap vs. peers like Novo Nordisk; that fuels mixed investor positioning rather than a clear buy/sell signal. Is Eli Lilly Stock Actually … Cheap?
• Negative Sentiment: Competitive and distribution risk: coverage on Amazon potentially entering GLP?1 distribution has raised concerns about pricing/market share dynamics for the lucrative weight?loss franchise. Lilly and Novo Stocks Are Tumbling. How Amazon Is Shaking Up the GLP-1 Game.
• Negative Sentiment: Legal and partnership noise: a court allowed Lilly’s lawsuit against a telehealth weight?loss drug seller to proceed, and Lilly ended a collaboration that returned rights to Rigel — items that create near?term headline risk and modest uncertainty. Eli Lilly can proceed with lawsuit against telehealth seller of weight-loss drugs

Wall Street Analysts Forecast Growth

LLY has been the subject of several recent analyst reports. Freedom Capital raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 10th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $1,285.00 target price on shares of Eli Lilly and Company in a report on Friday, March 6th. CICC Research upped their target price on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a report on Wednesday, February 11th. Argus upped their target price on Eli Lilly and Company from $930.00 to $1,200.00 and gave the company a “buy” rating in a report on Monday, February 9th. Finally, Loop Capital set a $1,200.00 target price on Eli Lilly and Company in a report on Tuesday, February 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,225.33.

Eli Lilly and Company Trading Up 2.0%

Shares of LLY stock opened at $921.01 on Thursday. The company has a 50 day moving average of $964.35 and a 200-day moving average of $984.09. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The firm has a market cap of $870.19 billion, a P/E ratio of 40.13, a PEG ratio of 1.07 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.48 by $0.06. The company had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. Eli Lilly and Company’s quarterly revenue was up 42.6% compared to the same quarter last year. During the same quarter last year, the business posted $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 33.95 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.